Quadro Engineering Corp.’s Post

IPD has released a new report predicting the 15 drugs likely to be selected for Medicare price negotiation for 2027 under the Inflation Reduction Act. This analysis, based on Medicare Part D spending data and third-party sales information, highlights drugs with substantial expenditures, including Ozempic, Trelegy Ellipta, and Xtandi, among others. With the drug list announcement expected by February 2025, stakeholders should be anticipating potential impacts on pricing and access as they make plans in the new year. Read the full report for a detailed analysis: https://lnkd.in/e7hzmvTZ #inflationreductionact #IRA #drugprices #medicare #pharmaceuticals #brandpharma #NovoNordisk #GSK #Pfizer #Astellas

🚨 Hot Topic Alert: Medicare Price Negotiations 🚨 We’re excited to share IPD’s latest report predicting drugs likely to be selected for Medicare price negotiation for 2027 under the Inflation Reduction Act (IRA). 📊 What’s Inside: A detailed analysis based on Medicare Part D spending data and third-party sales information. Highlights of drugs with substantial expenditures, including Ozempic, Trelegy Ellipta, and Xtandi, among others. Insights on how stakeholders should anticipate and prepare for the potential impacts on pricing and access ahead of the drug list announcement in February 2025. 🌟 Read the full report here: https://lnkd.in/gz4dcYfb Thank you for being part of this journey with us—we couldn’t do it without you! 🙌 #InflationReductionAct #IRA #DrugPrices #Medicare #Pharmaceuticals #BrandPharma #NovoNordisk #GSK #Pfizer #Astellas #IPDAnalytics

In August 2023, the U.S. Department of Health and Human Services (HHS), via the Centers for Medicare and Medicaid Services (CMS), announced the first 10 drugs covered under Medicare Part D selected for negotiation. The negotiated prices (i.e. maximum fair prices) for the first 10 selected drugs are expected to take effect on January 1, 2026, for eligible Medicare Part D beneficiaries. This report predicts the 15 drugs likely to be selected for negotiation for 2027 - a must read!

🌡️Minor fluctuations in temperature can significantly affect the quality and effectiveness of pharmaceuticals. The distinction between CRT and Ambient storage conditions, even by as little as 5 degrees, is crucial! Learn about the vital role your storage decisions play on your product's integrity in our newest blog post ➡️ https://gag.gl/LXqcNO #Pharmaceuticals #PharmaStorage #CRT #AmbientStorage #Alcami #temperature #warehousing #cGMP

🌡️Minor fluctuations in temperature can significantly affect the integrity and effectiveness of pharmaceuticals. The distinction between Controlled Room Temperature (CRT) and Ambient storage conditions is crucial, with just a 5-degree difference being pivotal! Learn about the vital importance of your storage decisions on your product in our newest blog post ➡️ https://gag.gl/LXqcNO #Pharmaceuticals #PharmaStorage #CRT #AmbientStorage #Alcami #temperature #warehousing #cGMP

🌡️Minor fluctuations in temperature can significantly affect the integrity and effectiveness of pharmaceuticals. The distinction between CRT and Ambient storage conditions, even by as little as 5 degrees, is crucial! Learn about the vital role your storage decisions play on your product's quality in our newest blog post ➡️ https://gag.gl/LXqcNO #Pharmaceuticals #PharmaStorage #CRT #AmbientStorage #Alcami #temperature #warehousing #cGMP

🌡️Minor fluctuations in temperature can significantly affect the integrity and effectiveness of pharmaceuticals. The distinction between CRT and Ambient storage conditions, even by as little as 5 degrees, is crucial! Learn about the vital role your storage decisions play on your product in our newest article ➡️ https://gag.gl/LXqcNO #Pharmaceuticals #PharmaStorage #CRT #AmbientStorage #Alcami #temperature #warehousing #cGMP

This is an excellent initiative by the FDA to enhance awareness about biosimilars. The expanding use of biosimilars represents an essential step in making high-quality, life-saving treatments more accessible and affordable for patients. By adhering to rigorous FDA quality standards, biosimilars demonstrate that cost savings do not compromise efficacy or safety. Their potential to address chronic conditions such as cancer, diabetes, and autoimmune diseases underscores their value in modern healthcare. Moreover, the introduction of interchangeable biosimilars further simplifies access, offering patients seamless treatment options while maintaining trust in quality. It's inspiring to see the healthcare ecosystem evolve with innovative solutions like biosimilars—providing sustainable options without sacrificing excellence. Initiatives like this reaffirm the importance of patient education and collaboration among healthcare providers. Thank you, FDA, for driving this transformation!

What are biosimilars? 🧬🔬 They're game-changers! Biosimilars increase access to life-saving treatments, reduce costs and promote sustainability in healthcare. #MovingMedicineForward #Healthierfutures

#Biosimilars provide a significant opportunity to expand patient access to essential medicines without sacrificing product quality. Data shows that when comparing a biosimilar to its FDA-approved reference product, there are no clinically meaningful differences in safety, purity, or potency. Like all biologics, biosimilars are tested in accordance with the Current Good Manufacturing Practice regulations enforced by the FDA. For more information about the quality, safety, and effectiveness of biosimilars, view the new educational resource from FDA and US Pharmacopeia: https://lnkd.in/dPRTAbBR   #GlobalBiosimilarWeek